Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy

Table 1 Patient characteristics

No.	Sex	Age (yr)	Location	Size (mm)	Metastases	UICC stage	Vaccine (times)	OS (d)	PFS (d)	HLA type						Best overall tumor response
										HLA-A		DRB1		DPB1
1	M	70	Body	22	Peritonitis	IV	35	582	440	02:01	24:02	04:05	15:02	05:01	09:01	Stable disease
2	M	68	Body	15	Liver, lymph nodes	IV	46	717	208	24:02	33:03	08:03	13:02	02:02	04:01	Stable disease
3	F	49	Head	18	Liver, peritonitis, lymph nodes	IV	7	133	26	02:01	24:02	04:05	09:01	02:02	05:01	Progressive disease
4	M	35	Body	25	Liver, lymph nodes	IV	6	283	147	02:01	-	09:01	15:01	02:01	05:01	Stable disease
5	F	72	Body	22	Peritonitis, lymph nodes	IV	14	215	109	02:06	24:02	08:02	12:01	02:01	05:01	Stable disease
6	F	69	Body-tail	45	Lymph nodes	IV	71+	1050+	545	24:02	33:03	13:02	15:01	04:01	13:01	Stable disease
7	M	39	Head-body	30	Peritonitis	IV	20	325	290	02:10	24:02	15:01	15:02	02:02	09:01	Stable disease

Stable disease conformation is determined at least for more than 2 mo. Ope: Operation; Cx: Chemotherapy; OS: Overall survival; PFS: Progression-free survival; HLA: Human leukocyte antigen.